Young age may predict a better outcome for children with diffuse pontine glioma

Cancer

Volumn 113, Issue 3, 2008, Pages 566-572

  Broniscer, Alberto ^a   Laningham, Fred H ^a   Sanders, Robert P ^a   Kun, Larry E ^a   Ellison, David W ^a   Gajjar, Amar ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Brainstem; Children; Pons; Radiation therapy; Treatment

Indexed keywords

CARBOPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ERLOTINIB; LONAFARNIB; TEMOZOLOMIDE; THALIDOMIDE; VINCRISTINE;

ARTICLE; ASTROCYTOMA; BRAIN STEM; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD CARE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CRANIAL NERVE PARALYSIS; DISEASE COURSE; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; PONS ANGLE TUMOR; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIODIAGNOSIS; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR LOCALIZATION;

AGE FACTORS; BRAIN STEM NEOPLASMS; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; EARLY DIAGNOSIS; FEMALE; GLIOMA; HUMANS; INFANT; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 49049118256     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23584     Document Type: Article

References (24)

1. Smith MA, Freidlin B, Ries LA, Simon R. Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst. 1998;90:1269-1277.
2. Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, Hammond GD. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery. 1993;33:1026-1029.
3. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7:241-248.
4. Cohen ME, Duffner PK, Heffner RR, Lacey DJ, Brecher M. Prognostic factors in brainstem gliomas. Neurology. 1986;36:602-605.
5. Kaplan AM, Albright AL, Zimmerman RA, et al. Brainstem gliomas in children. A Children's Cancer Group review of 119 cases. Pediatr Neurosurg. 1996;24:185-192.
6. Albright AL, Guthkelch AN, Packer RJ, Price RA, Rourke LB. Prognostic factors in pediatric brain-stem gliomas. J Neurosurg. 1986;65:751-755.
7. Freeman CR, Bourgouin PM, Sanford RA, Cohen ME, Friedman HS, Kun LE. Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy. Clinical characteristics and treatment related toxicities. The Pediatric Oncology Group. Cancer. 1996;77:555-562.
8. Milstein JM, Geyer JR, Berger MS, Bleyer WA. Favorable prognosis for brainstem gliomas in neurofibromatosis. J Neurooncol. 1989;7:367-371.
9. Broniscer A, Gajjar A, Bhargava R, et al. Brain stem involvement in children with neurofibromatosis type 1: role of magnetic resonance imaging and spectroscopy in the distinction from diffuse pontine glioma. Neurosurgery. 1997;40:331-337.
10. Guillamo JS, Monjour A, Taillandier L, et al. Brainstem gliomas in adults: prognostic factors and classification. Brain. 2001;124:2528-2539.
11. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than 3 years of age with malignant brain tumors. N Engl J Med. 1993;328:1725-1731.
12. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol. 2005;23:7621-7631.
13. Wagner S, Warmuth-Metz M, Emser A, et al. Treatment options in childhood pontine gliomas. J Neurooncol. 2006;79:281-287.
14. Barkovich AJ, Krischer J, Kun LE, et al. Brainstem gliomas: a classification system based on magnetic resonance imaging. Pediatr Neurosurg 1990-1991;16:73-83.
15. Fischbein NJ, Prados MD, Wara W, Russo C, Edwards MS, Barkovich AJ. Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. Pediatr Neurosurg. 1996;24:9-23.
16. Kieran MW, Packer RJ, Onar A, et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2007;25:3137-3143.
17. Moghrabi A, Kerby T, Tien RD, Friedman HS. Prognostic value of contrast-enhanced magnetic resonance imaging in brainstem gliomas. Pediatr Neurosurg. 1995;23:293-298.
18. Sanford RA, Freeman CR, Burger P, Cohen ME. Prognostic criteria for experimental protocols in pediatric brainstem gliomas. Surg Neurol. 1988;30:276-280.
19. Lenard HG, Engelbrecht V, Janssen G, Wechsler W, Tautz C. Complete remission of a diffuse pontine glioma. Neuropediatrics. 1998;29:328-330.
20. Thompson WD Jr, Kosnik EJ. Spontaneous regression of a diffuse brainstem lesion in the neonate. Report of 2 cases and review of the literature. J Neurosurg. 2005;102:65-71.
21. Pollack IF, Hamilton RL, Finkelstein SD, et al. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res. 1997;57:304-309.
22. Geyer JR, Finlay JL, Boyett JM, et al. Survival of infants with malignant astrocytomas. A report from the Childrens Cancer Group. Cancer. 1995;75:1045-1050.
23. Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: 2 challenges for the pediatric oncologist. Oncologist. 2004;9:197-206.
24. National Cancer Institute/U.S. National Institutes of Health: clinical trials Available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid= 504457&version=patient&protocolsearchid=3735276. Accessed May 6, 2008.